1. Park HJ, Georgescu SP, Du C, Madias C, Aronovitz MJ, Welzig CM, Wang B, Begley U, Zhang Y, Blaustein RO, Patten RD, Karas RH, Van Tol HH, Osborne TF, Shimano H, Liao R, Link MS, Galper JB. Parasympathetic response in chick myocytes and mouse heart is controlled by SREBP. Journal of Clinical Investigation 2008;118(1):259-271.
2. Park HJ, Zhang Y, Georgescu SP, Johnson KL, Kong D, Galper JB. Human umbilical vein endothelial cells and human dermal microvascular endothelial cells offer new insights into the relationship between lipid metabolism and angiogenesis. Stem Cell Reviews 2006;2(2):93-102.
3. Park HJ, Ward SM, Desgrosellier JS, Georgescu SP, Papageorge AG, Zhuang X, Barnett JV, Galper JB. Transforming growth factor β regulates the expression of the M² muscarinic receptor in atrial myocytes via an effect on RhoA and p190RhoGAP. Journal of Biological Chemistry 2006;281(29):19995-20002.
4. Tang D, Park HJ, Georgescu SP, Sebti SM, Hamilton AD, Galper JB. Simvastatin potentiates tumor necrosis factor β-mediated apoptosis of human vascular endothelial cells via the inhibition of the geranylgeranylation of RhoA. Life Sciences 2006;79(15):1484-1492.
5. Welzig CM*, Shin DG*, Park HJ*, Kim YJ, Saul JP and Galper JB. Lipid Lowering by Pravastatin Increases Parasympathetic Modulation of Heart Rate: Gαi2, a Possible Molecular Marker for Parasympathetic Responsiveness. *WCM, SDG and PHJ contributed equally to this work. Circulation 2003; 108: 2743-6.
6. Park HJ, Kong D, Iruela-Arispe L, Begley U, Tang D and Galper JB. 3-Hydroxy-3-Methylglutaryl CoA Reductase Inhibitors Interfere with Angiogenesis by Inhibiting Geranylgeranylation of RhoA. Circ. Res. 2002; 91: 143-150.
7.Park HJ, Begley U, Kong D, Yu H, Osborne T, and Galper JB. Role of Sterol Regulatory Element Binding Protein in the Regulation of Gai2 Expression in Cultured Heart Cells. Circ. Res. 2002; 91: 32-37.
8.Park HJ, Galper JB. 3-Hydroxy-3-Methylglutaryl CoA Reductase Inhibitors Upregulate Transforming Growth Factor b Signaling via Inhibition of Geranylgeranylation of RhoA GTPase in Cultured Heart Cells. Proc. Nat. Acad. Sci. 1999; 96: 11525-11530.
9. Park HJ, RajBhandary UL. Tetracycline-Regulated Suppression of Amber Codons in Mammalian Cells. Mol. Cell. Biol. 1998; 18:4418-4425.
10. Hecht HJ, Erdmann H, Park HJ, Sprinzl M, Schmid RD. Crystal structure of NADH oxidase from Thermus thermophilus. Nature Structural Biology 1995; 2:1109-1114.
Dr. Park earned his doctoral degree in Biochemistry from the University of Bayreuth, Germany, studying NAD(P)H oxidase from thermophiles in the Laboratory of Dr. Mathias Sprinzl. He then joined Dr. Tom RajBhandary’s laboratory of Molecular Biology at Massachusetts Institute of Technology in Cambridge, for a postdoctoral position working on the regulation of protein biosynthesis machinery in mammalian cells, and subsequently joined Dr. Jonas Galper’s laboratory in Division of Cardiovascular Research at Brigham and Women's Hospital / Harvard Medical School in Boston where he then served as an Instructor in Medicine at Harvard Medical School.
He has been actively investigating the role of lipid metabolism in angiogenesis and atonomic responsiveness using in vitro and in vivo models. In 2003, he joined Molecular Cardiology Research Institute as a Research Investigator and currently holds an appointment as an Assistant Professor in the Department of Medicine at Tufts University School of Medicine.
Laboratory of Lipid Metabolism and Cardiovascular Signaling
Molecular Cardiology Research Institute
Tufts Medical Center
800 Washington Street, Box #8486
Boston, MA 02111